Dyne Therapeutics (id:7925 DYN)
29.69 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 10:44:42 AM)
Exchange closed, opens in 22 hours 45 minutes
-1.03 USD (-1.03%)
4.84 USD (4.84%)
-12.34 USD (-12.34%)
-5.78 USD (-5.78%)
169.91 USD (169.91%)
31.43 USD (31.43%)
About Dyne Therapeutics
Market Capitalization 3.05B
Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
| Headquarters (address) |
1560 Trapelo Road Waltham 02451 MA United States |
| Phone | 781 786 8230 |
| Website | https://www.dyne-tx.com |
| Employees | 152 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | DYN |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 10.12 - 47.45 |
| Market Capitalization | 3.05B |
| P/E trailing | -7.52 |
| P/E forward | -9.49 |
| Price/Book | 4.33 |
| Beta | 1.10 |
| EPS | -3.58 |
| EPS United States (ID:6, base:3402) | 24.22 |